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ABSTRACT
Objective: To summarise the currently available literature and analyse available results of the
outcome of intraoperative frozen-section analysis (FSA) on upper urinary tract recurrence
(UUTR) after radical cystectomy (RC).
Materials and methods: A systematic review of the literature was performed according to the
Cochrane Reviews guidelines and in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) checklist. Articles discussing ureteric FSA
with RC were identified.
Results: The literature search yielded 21 studies, on which the present analysis was done. The
studies were published between 1997 and 2019. There were 10 010 patients with an age range
between 51 and 95 years. Involvement of the ureteric margins was noted in 2–9% at RC. The
sensitivity and specificity of FSA were ~75% and 99%, respectively. Adverse pathology on FSA
and on permanent section, prostatic urothelial carcinoma involving the stroma but not pro-
static duct, and ureteric involvement on permanent section were all more likely to develop
UUTR. Neither evidence of ureteric involvement nor ureteric margin status on permanent
section were significant predictors of overall survival.
Conclusion: Routine FSA is mandatory for a tumour-free uretero–enteric anastomosis and is
predictive of UUTR. To lower the UUTR, FSA is not necessary if the ureters are resected at the
level where they cross the common iliac vessels. FSA is indicated whenever the surgeon
encounters findings suspicious of malignancy, e.g. ureteric obstruction, periureteric fibrosis,
diffuse carcinoma in situ, induration or frank tumour infiltration of the distal ureter is discovered
unexpectedly during surgery, and prostatic urethral involvement.
Abbreviations CIS: carcinoma in situ; FSA: frozen-section analysis; HR: hazard ratio; PRISMA:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RC: radical cystectomy;
(UT)UC: (upper tract) urothelial carcinoma; UUT(R): upper urinary tract (recurrence)
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Introduction
Bladder cancer represents the fifth most common
malignancy in the Western world, with an incidence
of 80 470 in 2019 and amortality rate of 17 670 per year
in the USA alone [1,2].
The incidence of upper urinary tract recurrence
(UUTR) after radical cystectomy (RC) is reportedly 2.4–-
6.6%, and is associated with multiple clinical and
pathological risk factors including tumour multifocal-
ity, pathological stage, presence of carcinoma in situ
(CIS), and ureteric and urethral involvement [3–6].
To identify ureteric margin status, and thus ureteric
involvement, intraoperative frozen-section analysis
(FSA) during RC and then serial sectioning of the distal
ureter is performed. The validity of this approach in
improving UUTR outcomes is controversial, with sev-
eral publications questioning the accuracy of FSA and
the feasibility of achieving uninvolved ureteric margins
by sequential ureteric sectioning in light of the relative
rarity of UUTR after RC [7].
To this end, we aimed to conduct a systematic
review of the literature to evaluate the accuracy of
FSA to detect malignant ureteric margins at the time
of RC and to determine the impact of final margin
status obtained by a sequential sectioning strategy
on the risk of UUTR.
Materials and methods
Search strategy and study selection
The systematic review was performed according
to Cochrane Review Guidelines and in accordance
with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist [8].
The search strategy was conducted to find relevant
studies from the Medical Literature Analysis and
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Retrieval System Online (MEDLINE; 1966–2019), the
Excerpta Medica dataBASE (EMBASE; 1980–2019),
Google Scholar, and different urological journals. The
search was conducted in March 2019.
The search terms used included: ‘bladder cancer’,
‘upper tract recurrence’, ‘radical cystectomy ‘, and
‘intraoperative ureter frozen section’.
Mesh phrases included:
(‘Radical cystectomy’[Mesh]) AND “Upper tract recur-
rence “[Mesh]) ((“Upper tract recurrence “[Mesh]) AND
‘Radical cystectomy’[Mesh]) AND ‘Intraoperative ureter
frozen section’[Mesh]), (((‘Radical cystectomy’[Mesh])
AND ‘Upper tract recurrence’[Mesh]) AND ‘Intraoperative
ureter frozen section, Radical cystectomy’[Mesh]) AND
‘upper tract recurrence’[Mesh])
Inclusion criteria
1. All studies reporting on FSA of the distal ureter
during RC and the impact on UUTR.
2. Studies published in the English language over
the period 1980–2019.
Exclusion criteria
1. Animal studies and case reports.
2. Studies on RC and diversion that did not look at
the ureteric margins or UUTR.
The references of the retrieved papers were evalu-
ated for potential inclusion. Authors of the included
studies were contacted wherever data were not avail-
able or not clear. Two reviewers (K.S. and D.E.T.) identi-
fied all studies that adhered to the inclusion criteria for
full review. Each reviewer independently selected stu-
dies for inclusion. Disagreement between the extract-
ing authors was resolved by consensus or referred to
a third author (A.A.S.).
Data extraction and analysis
The objectives were to evaluate the impact of intrao-
perative FSA on UUTR after RC. The following variables
were extracted from each study: number of patients,
study origin and date, population demographics,
tumour characteristics, UUTR, overall and disease-
specific survival. The data from each study were
grouped into an analysis on an intention-to-treat
basis, to allow a numerical representation of the
results.
Results
The literature search yielded 39 studies, of which 18
were excluded because of irrelevance of data
(Figure 1), as the titles and abstracts of the studies
did not give sufficient data on UUTR after RC. All
included studies were retrospective studies, with no
randomisation or control groups.
Literature search (n = 39)
Articles excluded after screening of 
the title (n = 3) Potential articles for evaluation of 
abstract (n = 36)
Articles excluded after screening 
abstracts (n = 3)
Potential articles for evaluation of full 
manuscript (n = 33 )Articles excluded after screening full manuscripts 
(n = 12)
Included articles n = 21
noitacifitnedI
gnineercs
ytilibigil
E
dedulcnI
Figure 1. Flowchart of article selection.
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All studies reported on the variables indicated in the
data extraction section and are listed in Table 1
[1,3,4,6,7,9–23].
Characteristics of the included studies
The studies were published between 1997 and 2019.
There were 10 010 patients (84% male vs 16% female)
with an age range between 51 and 95 years. The
follow-up period ranged between 17 and 148 months.
Incidence of ureteric involvement at RC
The involvement of the ureteric margins at the time of
RC was reported in the range of 2% to 9% at the time of
RC [7,9–14,24].
An association in the incidence TCC and CIS in the
resected ureteric margins was found in 4.8%. In only
1.2% of them was it found at the level of iliac crossing
and more proximally resected ureteric segments [15].
There was a lot of evidence for an association between
bladder CIS and the incidence of ureteric involvement,
at 30% (107 patients) vs 9% (22) for patients with and
without bladder CIS, respectively [25,26].
The incidence of ureteric dysplasia was 6.9% in
patients who underwent RC with preoperative radio-
therapy compared to only 3.2% in patients who under-
went RC without preoperative irradiation [11].
Bilateral presentation of the disease, which was either
synchronous or metachronous, was reported in 13% of
all upper tract urothelial carcinomas (UTUCs). The results
from a study from Taiwan found that there were no
significant differences in contralateral recurrence-free
survival between various bladder tumour stages and
the grade of the tumour. Bladder cancer presence, either
previously metachronous or synchronous, did not pre-
dict contralateral recurrences (P = 0.14) [27].
Diagnostic characteristics and utility of FSA
(Figure 2 [15])
FSA positivity of the ureteric margins for malignancy
was found in the presence of CIS or invasive UC, while
negative margins were found in patients that had
reactive atypia or low-grade dysplasia [9].
The sensitivity and specificity of FSA was ~75% and
99%, respectively [9,12,15,16]. In comparison with final
histopathological analysis as the ‘gold standard’, the
false-positive and false-negative rates for FSA were 2%
and 6%, respectively [7,9,10,17,26].
A positive FSA, tumour multifocality [13], male gen-
der, CIS, and concomitant urethral malignancy
[6,9,12,16] were independent predictors of true distal
ureteric malignancy. Mucosal or ductal prostatic UC
(odds ratio 1.78, 95% CI 1.11–2.86), but not stromal
invasion, was associated with adverse ureteric margin
pathology at FSA in males after adjusting for age,
pathological grade and stage [11,13,15,17].
Compared to the corresponding permanent patho-
logical examinations, the intraoperative ureteric FSA
detected CIS in 17% [7] or in 75% [15].
Positive ureteric margins were noted in 9% of
patients on permanent pathological section and in
only 10% of those in whom intraoperative frozen sec-
tions were sent [9].
Number of frozen sections taken
Successful intraoperative conversion to benign pathol-
ogy, after two or more FSAs occurred in 77 ureters
(66.4%) [17]. Meanwhile, tumour-free margins were
achieved after a single subsequent resection in only
seven of 17 ureters (41.1%) and in the other 10 ureters
(58.9%) tumour-free margins were not achieved at FSA
despite subsequent re-sectioning of up to three times
[median (range) 1 (1–3); P = 0.48] [13].
The ‘serial step sectioning’ strategy was successful
in converting only 28% of ureters to a negative FSA
margin. Of these, 38 were ‘converted’ from a positive
margin on FSA to an uninvolved ureteric anastomotic
margin. Overall, 48 of 124 ureters (39%) with an initial
positive margin on FSA were converted to a negative
margin on permanent section (4% of 1217 ureters in
which FSA was performed) [9].
Are abnormal FSA ureteric margins associated
with UUTR?
UUTR occurred in 2–7% of patients undergoing RC
[3,4,9,28]. Some other studies noted an incidence of
2.3% [13,18,26,29]. Moreover, the risk is greater, up to
17%, in patients with CIS at the ureteric margin on FSA
[15,19]. UT carcinoma is rare and the commonest form
is UC, other histopathology, e.g. squamous cell carci-
noma and adenocarcinoma are very rare [30].
After adjustment for age, stage, grade, and presence
of CIS, in patients with adverse pathology on FSA and on
permanent section and prostatic UC involving the
stroma [hazard ratio (HR) 3.3, 95% CI 1.09–9.97;
P = 0.034), but not prostatic ducts (HR 2.54, 95% CI
0.74–8.78; P = 0.14) [17], and ureteric involvement on
permanent section (HR 1.8, 95% CI 1.1–3.1; P = 0.048),
were more likely to develop UUTR than those without
ureteric involvement [9].
There was 100% concordance with the side of UTUC
recurrence and the side of initial adverse pathology,
despite the successful conversion to benign intrao-
perative margins in 90% of cases (and benign perma-
nent sections of the proximal ureter) [17].
The renal pelvis was frequently the first site of
recurrence (68%) followed by the uretero–enteric ana-
stomosis (16%) and the ureters (16%) [9].
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Does the resection of abnormal margins reduce
the risk of uretero–enteric anastomotic
recurrence?
The incidence of an invasive tumour recurrence at the
uretero–enteric anastomosis after RC is ~1%
[9,11,31,32].
Ureteric margin CIS was most frequently found in
patients with multifocal tumours, and those with high-
stage and high-grade disease [14].
No patient, with either dysplasia or CIS developed
a ureteric malignancy in the area of uretero–enteric
anastomosis after a median follow-up of 6 years
[10,11]. Conversely, of CIS diagnosed on the first ure-
teric FSA, one patient had recurrence at the site of
uretero–enteric anastomosis. In one patient ureteric
FSA was normal, whereas in the other patient CIS was
diagnosed [15,19,20].
On the other hand, recurrent transurethral resection
of bladder tumour (TURBT) indicates recurrent tumour,
unhealthy urothelium and high-grade tumour, which
are all risk factors for positive FSA and increase risk of
recurrence. From different articles there was
a statistically significant variance in recurrence in
patients with a history of multiple urothelial recur-
rences or with multifocal tumours when compared to
patients who has a solitary lesion at pre-RC TURBT
[19,27]
Value of FSA on survival
Neither evidence of ureteric involvement (HR 0.9; 95%
CI, 0.7–1.1) nor ureteric margin status (HR 1.0, 95% CI
0.7–1.3) on permanent section were significant predic-
tors of overall survival [9,17,33].
Sanderson et al. [29] reported a survival rate of 73%
in patients with low tumour stages (pTa–pT1) at
a median of 3.4 years, meanwhile in advanced stages
(pT3) only 8% were alive at a median of 1.2 years. As
Figure 2. Template of how to perform a frozen-section examination [15].
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the risk of ureteric malignancy at the time of RC is
highest in the distal part of the ureter [15] and neoad-
juvant chemotherapy has the potential of tumour
down-staging, patients with evidence of tumour invol-
vement of the distal ureter in the preoperative staging
may derive benefit from neoadjuvant chemotherapy
to reduce the risk of malignant ureteric margins at RC
[34]. FSA of the distal ureters at RC is however unlikely
to be positive unless the bladder cancer stage is
≥T2 [33].
When comparing the stages of N0 vs N+ (including
all patients with lymph node involvement by the
urothelial lesion) there is a large difference in incidence
in both groups. Patients with nodal involvement have
potential short-term follow-up related to their high
mortality rate, so we cannot conclude the precise
effect of nodal stage on UUTR [35].
Cost, cost-effectiveness, and alternatives to FSA
Each ureteric FSA generates a charge somewhere in
the vicinity of 400 USD and may increase the overall
pathology charges by 25% or 50% if one or two FSAs
are evaluated per each ureter [9,10]. The cost to iden-
tify one patient with CIS or solid UC of the ureter on
FSA was 6471 USD [12].
Discussion
The investigators hypothesised that FSA of the ureteric
margins at the time of RC would support complete
removal of the tumour, which would in turn improve
survival of patients with bladder cancer. Culp et al. [21]
first discussed this matter after discovering that 38 of
231 patients (17%) had unexpected ureteric epithelial
abnormalities at RC, so they suggested that unappre-
ciated CIS could result in recurrence in the remaining
ureter and renal pelvis, although their series was small
and a lot of the patients had advanced disease at
follow-up.
The initial stimulus for FSA was to ensure a cancer-
free anastomosis, which supposedly would transform
into reduced UUTR rates and longer cancer-free survi-
val. Yet, controversy remains concerning the value of
ureteric margin FSA in achieving such goals due to the
rarity of UUTR [15]. FSA is mostly indicated whenever
the surgeon encounters findings suspicious of malig-
nancy, e.g. ureteric obstruction, periureteric fibrosis,
diffuse CIS, induration or frank tumour infiltration of
the distal ureter that is discovered during the surgery,
and involvement of the prostatic urethra [10,11]. FSA
of the ureters is not necessary if the ureters are
resected at the level where they cross the common
iliac vessels [15].
An UUTR was defined as any documented radio-
graphic, cystoscopic, or pathologically confirmed
recurrence in the kidneys, ureters, or urinary diversion.
Documentation of a mass within the ureter, renal pel-
vis or ureteric wall thickening with enhancement on
intravenous contrast administration was considered
radiographic evidence of urothelial recurrence. While,
‘ureteric wall thickening without enhancement’, ‘ure-
teric streaking’, ‘streaky changes around the ureter’,
‘periureteric stranding’, ‘fullness/infiltration around
the ureter’, ‘ureteric dilation’, ‘renal masses not invol-
ving the renal pelvis’, or ‘worsening hydronephrosis’,
were considered insufficient evidence of urothelial
recurrence [9].
An association with TCC and CIS was found in 4.8%
in the wide range of the distal ureter and in 1.2% at the
level of iliac cross and more proximally resected ure-
teric segments [15]. Evidence of bladder CIS is asso-
ciated with higher incidence of ureteric involvement
(30% vs 9%, for patients with and without bladder CIS,
respectively) [25,26].
The positivity of ureteric margins for malignancy is
evident in the presence of CIS or invasive UC, while,
negative when histological analysis demonstrated
reactive atypia or low-grade dysplasia [9].
It has been suggested that a more proximal ureteric
segment can be excised to assure a tumour-free ure-
tero–enteric anastomosis, evident by the highest inci-
dence of urothelial malignancies in the distal ureter
[31]. Therefore, resection of the ureters at the level
where they cross over the common iliac arteries should
increase the probability of a tumour-free uretero–
enteric anastomosis [15].
The sensitivity and specificity of FSA was ~75% and
99%, respectively [9,12,15,16]. In comparison with final
histopathological analysis as the ‘gold standard’, the
false-positive and false-negative rates for frozen sec-
tion were 2% and 6%, respectively [7,9,10,17,26].
Compared to the corresponding permanent patholo-
gical examinations, the intraoperative ureteric FSA can
only detect CIS in 17% [7] or in 75% [15].
The incidence of an invasive tumour recurrence at
the uretero–enteric anastomosis after RC was ~1%
[9,11,31,32]. Ureteric margin CIS was most frequently
found in patients with multifocal tumours and those
with high-stage and high-grade disease [14].
Tumour multifocality [13], male gender, CIS, and
concomitant urethral malignancy [6,9,12,16] were
independent predictors of true distal ureteric malig-
nancy. Mucosal or ductal prostatic UC, but not stromal
invasion, was associated with adverse ureteric margin
pathology at FSA [11,13,15,17]. On the other hand,
recurrent TURBTs indicate recurrent tumour, unhealthy
urothelium and high-grade tumour, which all are risk
factors for positive FSA and increase the risk of recur-
rence. From different articles there was a statistically
significant variance in recurrence in patients with
a history of multiple urothelial recurrences or with
multifocal tumours when compared with patients
who had a solitary lesion at pre-RC TURBT [19].
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The presence of a JJ stent could be a risk factor for
UUTR if drainage of the UUT is performed. Kiss et al.
[36] reported UUTR in 1005 patients who had conco-
mitant bladder tumours, 114 (11%) of whom had drai-
nage, including in 53 (46%) with JJ stenting and 61
(54%) with percutaneous nephrostomy. They reported
UUTR in 31 patients (3%) at a median of 17 months
after RC, including seven of the 53 (13%) in the JJ-stent
group, 0% in the nephrostomy group, and 24 of 891
(3%) in the no drainage group. Multivariate regression
analysis revealed a higher risk of UUTR if patients
underwent JJ stenting (HR 4.54, 95% CI 1.43–14.38;
P = 0.01) [36].
The number of frozen sections that should be taken
during RC is variable. One biopsy may be sufficient, but
two or more may be needed in order to reach benign
pathology that at the same time does not affect ure-
teric length [13,17].
The ‘serial step sectioning’ strategy involves serial
cutting of the distal ureter, beyond the last 0.5 cm of
the vesico-ureteric junction, until reaching a negative
FSA. Sequential sectioning of the ureter aims to elim-
inate all cancer tissue, yet, this objective remains
incomplete if tumour tissue remains at the primary
surgical site or node metastases are present. It was
successful in converting up to 28% of ureters to
a negative FSA margin [9]. A negative FSA margin in
the majority of patients was not reached during
sequential ureteric resection due to technical consid-
erations in anastomosing ureters that are too short, the
limited length of residual ureters, and minimising
potential complications of uretero–enteric anastomo-
tic strictures [7,10].
The FSA should also be evaluated from a cost per-
spective. Each ureteric FSA generates a charge some-
where in the vicinity of 400 USD [9,10,12]. Any costs can
be justified when one considers the cost implications of
further treatments or surgery if recurrences occur.
An UUTR occurred in 2–7% of patients undergoing
RC [3,4,9,13,26,28,29]. Moreover, the risk increases in
patients with CIS at the ureteric margin on FSA [15].
Concomitant UUT tumour with bladder cancer occurs
in 0.7–2.6% [37].
After adjustment for age, stage, grade, and pre-
sence of CIS, patients with adverse pathology on FSA
and on permanent section and prostatic UC involving
the stroma, but not prostatic ducts [17], and ureteric
involvement on permanent section, were more likely
to develop UUTR than those without ureteric involve-
ment [9]. Both a positive initial and final margin status
was associated with UUTR. Those patients with
a positive initial margin were 5.3-times more likely to
experience an UUTR than those with a negative initial
margin. Of those with a positive initial margin, patients
with a positive final margin were 60% more likely to
experience an UUTR than those with a negative final
margin [22].
The renal pelvis was frequently the first site of
recurrence (68%), followed by the uretero–enteric ana-
stomosis (16%), and the ureters (16%) [9]. The defini-
tive treatment for such evident recurrence is either
nephroureterectomy or ureteric resection and the
creation of an ileal ureter, if a solitary renal unit is the
actual situation [17,23].
Neither evidence of ureteric involvement (HR 0.9,
95% CI 0.7–1.1) nor ureteric margin status (HR 1.0, 95%
CI 0.7–1.3) on permanent section were significant pre-
dictors of overall survival [9,17]. However, patients with
CIS at the ureteric margin that was not diagnosed by
FSA subsequently might have pelvic recurrence, distant
metastases, and radiographic evidence of UUTR [10,15].
As the risk of ureteric malignancy at the time of RC is
highest in the distal part of the ureter [15] and neoad-
juvant chemotherapy has the potential of tumour
down-staging, patients with evidence of tumour invol-
vement of the distal ureter at preoperative staging
may derive benefit from neoadjuvant chemotherapy
to reduce the risk of malignant ureteric margins at
RC [34].
Conclusion
Routine FSA should not be ignored, in order to achieve
tumour-free uretero–enteric anastomosis and to
decrease the incidence of UUTR. It is not required if
the ureters are resected at the level above where they
cross the common iliac vessels. It is indicated when-
ever the surgeon encounters findings suspicious of
malignancy, e.g. ureteric obstruction, periureteric
fibrosis, diffuse CIS, induration or frank tumour infiltra-
tion of the distal ureter is discovered unpredictably
during surgery, and prostatic urethral involvement.
Tumour multifocality, male gender, CIS, and concomi-
tant urethral malignancy were independent predictors
of true distal ureteric malignancy. Mucosal or ductal
prostatic UC, but not stromal invasion, were associated
with adverse ureteric margin pathology at FSA.
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